GALT has updated their NASH-CX presentation. Click here to view the form 8-K and presentation. On March 06, 2019 GALT filed registration statements of a rights offering of common stock and … [Read more...] about GALT Updates NASH-RX Presentation
Galetin Therapeutics
GALT Director Sells 30K Shares
Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. A form-4 just filed on 02/04/2019 by Galectin Therapeutics (Nasdaq: GALT) reports that GALT director … [Read more...] about GALT Director Sells 30K Shares
MS Morning Update
Leave a comment and click here to subscribe for MS article alerts and our newsletter! MRK Exercises Option For NGM Bio's Investigational Insulin Sensitizer-NGM313 January 3rd, 2019 MRK … [Read more...] about MS Morning Update
Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
VSTM Overaction to Black Box Label Creates Buying Opportunity
For months Verastem Oncology (VSTM) investors have been eagerly awaiting the FDA's decision on it's lead product Duvelisib; a PI3K-δ (delta) and PI3K-γ (gamma) inhibitor that was granted Orphan Drug … [Read more...] about VSTM Overaction to Black Box Label Creates Buying Opportunity
Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
Today September 20th Galectin Therapeutics (NASDAQ: GALT) announced promising results from their phase 1b clinical trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial. … [Read more...] about Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
GR-MD-02: Keytrua’s Partner, Cancer’s Nemesis
Tumors excrete elevated level of galectin-3 Galectin-3 diminishes T-cells’ ability to kill tumor cells Galectin-3 aids in cancer progression GR-MD-02 is safe, effective, and … [Read more...] about GR-MD-02: Keytrua’s Partner, Cancer’s Nemesis
GALT is Primed for Acquisition or Partnership
Overview Galectin Therapeutics (NASDAQ GALT $5.96) is a leader in the development of a treatment for Non-Alcoholic SteatoHepatitis, an unmet medical need worth billions. Their star drug … [Read more...] about GALT is Primed for Acquisition or Partnership
You must be logged in to post a comment.